How to Leverage PBPK Modeling and Simulation in Drug Research and Development
Learn how PBPK modeling and simulation in drug research and development reduces clinical burden, supports…
CertaraMay 12, 2026
PBPK Modeling in Pregnancy: Improving Drug Dosing Without Clinical Trials
The FDA is shifting toward approving drugs based on a single pivotal trial supported by…
CertaraMay 12, 2026
The one-trial era: what the FDA’s shift signals for the future of drug development
The FDA is shifting toward approving drugs based on a single pivotal trial supported by…
CertaraMay 6, 2026
How Pharma Can Transition to Non-animal Studies for Investigational Drugs
Pharma companies can ease the transition to non-animal studies for investigational drugs by leveraging NAMs…
CertaraMay 5, 2026
From Models to Impact: What QSPC 2026 Revealed About the Future of Drug Development
Explore Certara’s insights from QSPC 2026, including virtual patients, regulatory adoption, AI in QSP, and…
CertaraApril 28, 2026
Top 10 Benefits of Simcyp® Simulator for Drug Development
JTVCdGVhbV9qdW1wX2xpc3QlNUQ= April 23, 2026 Physiologically based pharmacokinetic (PBPK) modeling has evolved from an emerging methodology…
CertaraApril 23, 2026
Final ICH M15 Guidance: Aligning MIDD with Global Regulatory Expectations
Watch this on-demand webinar to learn how the final ICH M15 guidance is shaping Model-Informed…
CertaraApril 2, 2026
